• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Ardea Biosciences, Inc. (RDEA) - Financial and Strategic SWOT Analysis Review Product Image

Ardea Biosciences, Inc. (RDEA) - Financial and Strategic SWOT Analysis Review

  • Published: September 2011
  • Region: Global
  • 41 pages
  • GlobalData

FEATURED COMPANIES

  • Array BioPharma Inc.
  • Insmed Incorporated
  • XOMA Ltd.
  • MORE

Ardea Biosciences, Inc. (RDEA) - Financial and Strategic SWOT Analysis Review

Summary

Ardea Biosciences, Inc. (Ardea Biosciences) is a biotechnology company principally engaged in the discovery and development of therapeutics moleculefor the treatment of HIV, gout, cancer and inflammatory diseases. Ardea Biosciences principally focuses on in development of antimicrobial drugs. Its lead product candidate, Lesinurad formerly known as RDEA594 has completed Phase 2 clinical development and is being developed for the treatment of hyperuricemia and gout. Ardea Biosciences has intellectual property base acquired from Valeant Research and Development, Inc. for the development of products. Ardea Biosciences is headquartered in California, the US.

Ardea Biosciences, Inc. Key Recent Developments

Aug 05, 2011 Ardea Biosciences Reports Total Revenue Of $2.2m For Q2 2011
May 09, 2011 Ardea Biosciences Reports Net Loss Of $15.2m For Q1 2011
Apr 25, 2011 Ardea Biosciences To Present Additional Data From Completed Phase IIb Combination Study Of Lesinurad At Annual European Congress Of Rheumatology
Mar 11, 2011 Ardea Biosciences Reports Revenues Of $17.3m For READ MORE >



List of Tables
List of Figures
Section 1 - About the Company
Ardea Biosciences, Inc. - Key Facts
Ardea Biosciences, Inc. - Key Employees
Ardea Biosciences, Inc. - Key Employee Biographies
Ardea Biosciences, Inc. - Major Products and Services
Ardea Biosciences, Inc. - Pharmaceutical Pipeline Products Data
Ardea Biosciences, Inc., Pipeline Products by Therapy Area
Ardea Biosciences, Inc., Pipeline Products by Development Phase
Ardea Biosciences, Inc. - History
Ardea Biosciences, Inc. - Company Statement
Ardea Biosciences, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Ardea Biosciences, Inc. - Business Description
Ardea Biosciences, Inc. - SWOT Analysis
SWOT Analysis - Overview
Ardea Biosciences, Inc. - Strengths
Strength - Focused Research and Development
Strength - Strong Patent Portfolio
Strength - Global Agreement with Bayer HealthCare
Strength - Expanding Liquidity Position
Weakness - Geographical Concentration
Weakness - Decreased Efficiency
Weakness - Lack of Internal Manufacturing Capabilities
Opportunity - Market Potential: HIV
Opportunity - Growing Oncology Treatment Market
Opportunity - Targeting the Treatments for Gout
Opportunity - Positive Clinical Results
Threat - Tightening of FDA’s Regulatory Oversight
Threat - Competitive Pressures
Threat - Lack of Marketable Products
Ardea Biosciences, Inc. - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Ardea Biosciences, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
Ardea Biosciences, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2005 to YTD 2011
Ardea Biosciences, Inc., Recent Deals Summary
Section 5 – Company’s Recent Developments
Aug 05, 2011: Ardea Biosciences Reports Total Revenue Of $2.2m For Q2 2011
May 09, 2011: Ardea Biosciences Reports Net Loss Of $15.2m For Q1 2011
Apr 25, 2011: Ardea Biosciences To Present Additional Data From Completed Phase IIb Combination Study Of Lesinurad At Annual European Congress Of Rheumatology
Mar 11, 2011: Ardea Biosciences Reports Revenues Of $17.3m For Q4 2010
Nov 09, 2010: Ardea Biosciences Reports Net Loss Of $18.2m For Q3 2010
Nov 02, 2010: Ardea Biosciences Receives $733,438 Grant From US Government Under Patient Protection And Affordable Care Act
Aug 06, 2010: Ardea Biosciences Reports Net Loss Of $12.8 Million For Q2 2010
Jun 18, 2010: Positive Phase 2 Data On Rdea594, Ardea Biosciences Lead Product Candidate For The Treatment Of Hyperuricemia And Gout, Presented At The Annual European Congress Of Rheumatology
May 07, 2010: Ardea Reports Net Loss Of $10 Million For Q1 2010
Apr 12, 2010: Ardea Biosciences Names Stephen Davis As Executive Vice President And COO
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Ardea Biosciences, Inc., Key Facts
Ardea Biosciences, Inc., Key Employees
Ardea Biosciences, Inc., Key Employee Biographies
Ardea Biosciences, Inc., Major Products and Services
Ardea Biosciences, Inc., Number of Pipeline Products by Therapy Area
Ardea Biosciences, Inc., Number of Pipeline Products by Development Stage
Ardea Biosciences, Inc., Pipeline Products By Therapy Area and Development Phase
Ardea Biosciences, Inc., History
Ardea Biosciences, Inc., Subsidiaries
Ardea Biosciences, Inc., Key Competitors
Ardea Biosciences, Inc., Ratios based on current share price
Ardea Biosciences, Inc., Annual Ratios
Ardea Biosciences, Inc., Interim Ratios
Ardea Biosciences, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
Ardea Biosciences, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2005 to YTD 2011
Ardea Biosciences, Inc., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Ardea Biosciences, Inc., Pipeline Products by Therapy Area
Ardea Biosciences, Inc., Pipeline Products by Development Phase
Ardea Biosciences, Inc., Performance Chart (2006 - 2010)
Ardea Biosciences, Inc., Ratio Charts
Ardea Biosciences, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
Ardea Biosciences, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2005 to YTD 2011

Vertex Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc.
Insmed Incorporated
XOMA Ltd.
Idenix Pharmaceuticals, Inc.
Array BioPharma Inc.

Note: Product cover images may vary from those shown

RELATED PRODUCTS